In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 251 to 260 of 342

TitleTypeExpected publication date
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidanceTBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidanceTBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Technology appraisal guidanceTBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356Technology appraisal guidanceTBC
Renal cell carcinoma Pathways Pilot [ID6186]Technology appraisal guidanceTBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All